Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04998942
Other study ID # 2021P001285
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 11, 2021
Est. completion date June 2023

Study information

Verified date May 2023
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypertensive disorders of pregnancy (HDP) are now well-recognized risk factors for adverse outcomes in the postpartum period and for development of future cardiovascular disease (CVD). Postpartum BMI has emerged as a strong predictor of both short- and long-term blood pressure (BP) control in observational studies suggesting that earlier postpartum lifestyle modifications may be instrumental in future CVD risk reduction in women with HDP. While such lifestyle modifications are recognized as critical for postpartum health, implementation and engagement of postpartum women remains a challenge as new mothers face greater barriers to in-person care given childcare responsibilities. The proposed study will investigate the acceptability of a virtual cardiac wellness program and its impact on weight, lifestyle modifications, cardiometabolic health, patient engagement, and outcomes following HDP as compared to the standard of care for postpartum women at Massachusetts General Hospital.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date June 2023
Est. primary completion date March 13, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women with a diagnosis of HDP inclusive of gestational hypertension, preeclampsia, eclampsia, and chronic hypertension with superimposed preeclampsia - Pre-pregnancy BMI >18.5 - Age = 18 years - Access to a phone - Delivery at MGH and receive longitudinal obstetrics care at MGH Exclusion Criteria: - Moderate or severe cognitive impairment - Current incarceration - Pre-pregnancy BMI = 18.5 - Women without a documented pre-natal weight or weight recorded 1 year prior to pregnancy - Baseline exercise of > 150 minutes/ week at the time of study enrollment - Not cleared for exercise by primary OB

Study Design


Intervention

Behavioral:
virtual cardiac wellness program
Participants assigned to this arm will participate in the experimental intervention.
Placebo comparator
Participants assigned to this arm will participate in a placebo intervention.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Percent of scheduled postpartum obstetric visits attended in each treatment group Percent of scheduled postpartum obstetric visits attended by patients in each treatment group 1 year
Other Percent of patients who attend a primary care doctor visit in each treatment group Percent of patients who attend a primary care doctor visit in the 1st postpartum year in each treatment group 1 year
Other Percent of patients lactating in each treatment group at 6 months postpartum Percent of patients lactating in each treatment group at 6 months postpartum 6 months
Other Percent of patients lactating in each treatment group at 1 year postpartum Percent of patients lactating in each treatment group at 1 year postpartum 1 year
Other Percent of patients taking prescribed medications in each treatment group Percent of patients who were taking prescribed medications (as assessed by refill requests documented in Epic) in each treatment group 6 months
Other Percent of study visits completed by patients in the intervention arm Percent of study visits (out of the nutrition consultations and EP virtual visits) completed by patients in the intervention arm 6 months
Other Acceptability of the intervention Acceptability of the intervention among study participants as assessed by exit survey (7 questions, 0= Strongly disagree, 4= Strongly agree, Max score= 28). A higher score means a better outcome. 6 months
Primary Postpartum weight loss at 6 months postpartum Postpartum weight loss (Last prenatal visit weight- weight at 6 months postpartum) as a proportion of weight gained during pregnancy (Last prenatal visit weight- either 1st prenatal weight or pre-pregnancy weight within 1 year) 1 year
Secondary Postpartum weight loss at 1 year postpartum Postpartum weight loss (from last prenatal visit weight) at 1 year postpartum as a proportion of weight gained during pregnancy 1 year
Secondary Return to pre-pregnancy weight Proportion of women who return to pre-pregnancy weight at 6 months postpartum 6 months
Secondary Return to pre-pregnancy weight Proportion of women who return to pre-pregnancy weight at 1 year postpartum 1 year
Secondary Changes in blood pressure Systolic and diastolic blood pressure at 6 months postpartum 6 months
Secondary Changes in blood pressure Systolic and diastolic blood pressure at 1 year postpartum 1 year
Secondary Change in sedentary time Change in self-reported sedentary time from study enrollment and study completion (completion of the study intervention). Decreased sedentary time means better outcomes. 6 months
Secondary Change in physical activity as assessed by self-reported physical activity survey Change in self-reported physical activity from study enrollment and study completion as assessed by self-reported physical activity survey (Days per week exercised, length of exercise sessions). Increased physical activity means a better outcome. 6 months
Secondary Change in physical activity as assessed by modified Duke Activity Status Index Change in self-reported physical activity from study enrollment and study completion as assessed by modified Duke Activity Status Index (6 question yes/no survey, score ranges from 0-31.5). A higher score means a higher functional status. 6 months
Secondary Change in stress as assessed by self-reported stress survey Change in self-reported stress from study enrollment and study completion as assessed by self-reported stress survey (3 questions on scale of 0-4 [0= Never experience stress, 4= Constant stress], Max score=12). A lower score means a better outcome. 6 months
Secondary Change in stress as assessed by American Heart Association Cardiovascular Disease Go Red Questionnaire Change in self-reported stress from study enrollment and study completion as assessed by American Heart Association Cardiovascular Disease Go Red Questionnaire (11 questions on scale of 0-4 [0= None of the Time, 4= All of the Time], Max score=44). A lower score means a better outcome. 6 months
Secondary Change in self efficacy for diet Change in self efficacy to eat a healthy diet from study enrollment and study completion assessed by an 8-question survey rating confidence for motivating oneself to do tasks relating to eating healthy consistently for at least 6 months (Range 1 [I could not do it] to 5 [I could do it], Max score= 40). A higher score means a better outcome. 6 months
Secondary Change in self efficacy for physical activity assessed by questionnaire Change in self efficacy toward achieving and maintaining a healthy level of physical activity assessed by an 8-question survey rating confidence for motivating oneself to do tasks related to physical activity consistently for at least 6 months (Range 1 [I could not do it] to 5 [I could do it], Max score= 40). A higher score means a better outcome. 6 months
Secondary Change in cardiovascular disease knowledge assessed by American Heart Association Cardiovascular Disease Go Red Questionnaire Change in knowledge on the American Heart Association Cardiovascular Disease Go Red Questionnaire (modified for the postpartum population) from study enrollment and study completion (5 questions total: 4 questions on scale of 0-4 [0= Very well informed, 4= Not at all informed], Max score=16, 16-part question about the causes of heart disease [1= Yes, 2 =No], Max score = 32). A lower score means a better outcome. 6 months
Secondary Change in quality of diet assessed by Dietary Approaches to Stop Hypertension (DASH) score Change in quality of diet assessed by Dietary Approaches to Stop Hypertension (DASH) score from study enrollment and study completion (DASH score range 0 [no targets met] to 9 [all targets met]). A higher score means a better outcome. 6 months
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting NCT03313024 - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting NCT04990141 - Molecular Screening Method for Preeclampsia (PREMOM)
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT02923206 - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis N/A
Withdrawn NCT05016440 - Lisinopril for Renal Protection in Postpartum Preeclamptic Women N/A
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Terminated NCT02558023 - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Phase 3
Completed NCT02554604 - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Not yet recruiting NCT02541110 - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler N/A
Completed NCT02854501 - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Recruiting NCT02337049 - Preeclampsia Subtypes and Surrogate Markers of CVD Risk N/A
Recruiting NCT02247297 - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed NCT02238704 - Cornell University-Micronutrient Initiative Calcium Supplementation Study N/A
Completed NCT01195441 - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound N/A
Withdrawn NCT01179542 - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR N/A
Completed NCT00456118 - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting NCT00117546 - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A